Intravenous Iron Drugs Market - Growth, Trends, Covid-19 Impact, And Forecasts (2022 - 2027)

Intravenous Iron Drugs Market - Growth, Trends, Covid-19 Impact, And Forecasts (2022 - 2027)

The global intravenous iron drugs market is expected to grow at a significant CAGR of 8.35% during the forecast period.

During the pandemic, there is a slight decline in the intravenous iron drugs market due to the disruption of the supply chain and manufacturing process. But the market recovered soon and has grown subsequently, as there was a high demand for intravenous iron drugs, due to the increased risk of Chronic Kidney Failure (CKD)-related anemia in COVID-19 patients. Furthermore, as per the article published in 2021 under the title “Successful Treatment of Iron Deficiency Anemia with Ferric Carboxymaltose in an Elderly Patient with Multiple Comorbidities and COVID-19”, an older patient with numerous concomitant conditions who was hospitalized for COVID-19 was treated for iron deficient anemia with ferric carboxymaltose (Ferinjectâ, Vifor International). The medication caused the hemoglobin (Hb) to return to normal, the iron reserves to quickly restock, and the transferrin saturation to simultaneously improve. In cases of severe patients with diffuse coagulopathy, like the one in the present case, ferric carboxymaltose can be thought of as a viable option to treat anemia while a patient is being treated in a hospital for COVID-19 and avoid transfusion regimens. Hence as per the facts mentioned above, COVID-19 had a significant impact on the intravenous iron drugs market.

Certain factors driving the market growth include the increasing prevalence of target diseases such as chronic kidney disease-related anemia, irritable bowel syndrome, cancer-related anemia, disadvantages of oral iron drugs, and an increasingly aging population. As per the article published in 2022 under the title “Intravenous Iron Supplementation for the Treatment of Chemotherapy-Induced Anemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials”, the study showed that IV iron for the treatment of cancer-induced anemia (CIA) reduces the need for red blood cells (RBC) transfusions and is not associated with adverse events. IV iron for the treatment of cancer-induced anemia should be considered in clinical practice.

Furthermore, government initiatives, research, and development in the field of IV iron drugs and the presence of competitors boost the market growth. For instance, in February 2021, The National Medical Products Administration (NMPA) in China approved Monofer (Ferric Derisomaltose) injection 100 mg/mL developed by Pharmacosmos. Monofer is an intravenous iron that is used in adult patients who have an intolerance to oral iron or unsatisfactory response to oral iron, or when there is a clinical need to administer iron quickly.

Apart from this, iron deficiency anemia is another common consequence of inflammatory bowel disease (IBD). Intravenous iron drugs are preferred for the treatment of IBD associated with iron deficiency anemia. Oral iron supplementation is the most frequent iron-deficient anemia treatment; however, it has been linked to gastro intestinal (GI) side effects such as constipation and bloating. Due to the lack of exposure to the intestinal lumen, intravenous iron drugs do not elicit gastro intestinal adverse effects. Therefore, chronic diseases such as CKD and IBD have resulted in persistent and prolonged anemia, fueling the growth of the intravenous iron drugs market.

As per the factors mentioned above, the studied market is anticipated to grow over the forecast period. However, adverse reactions associated with intravenous Iron drugs restrain the market growth.

Key Market TrendsFerric Carboxy Maltose Segment is Expected to Hold a Major Market Share in the Intravenous Iron Drugs Market

FCM (Ferric Carboxy Maltose) is a new parenteral iron drug that is the first of its kind to be approved by the United States Food and Drug Administration (FDA) for quick and high-dose iron replenishment. It is used as an iron replacement drug for the treatment of iron deficiency anemia (IDA) in adult patients with oral iron intolerance, a poor response to oral iron, or non-dialysis-dependent chronic kidney disease.

Treatment for iron deficiency anemia with FCM aims to restore normal hemoglobin (Hb) levels, replenish iron storage, and normalize red cell levels. Other objectives include reducing anemia-related symptoms and improving health-related quality of life. Ferric carboxy maltose is a new therapy option that has a low risk of hypersensitivity events and is well tolerated at high doses besides being safe, effective, and cost-efficient compared to other available intravenous iron drug treatments. Several studies have assured the safety and effectiveness of FCM over other intravenous iron drugs. For instance, as per the article published in 2022 under the title “Efficacy and Safety of Ferric Carboxymaltose in the Management of Iron Deficiency Anemia: A Multi-Center Real-World Study from India”, FCM effectively, safely, and quickly treats patients with moderate-to-severe anemia in about 4 weeks. The clinical use of FCM in real-world scenarios is supported by doctors' favorable clinical impressions of its efficacy and safety. Hence such development and studies related to FCM are likely to boost the market growth over the forecast period.

Furthermore, the presence of competitors, product launches, research, and development in the field of FCM fuels market growth. For instance, the clinical trial report published in 2022 under the title “Randomized controlled trial to compare injection ferric carboxymaltose and oral iron in reducing postpartum anemia: A multicenter, pilot study”, stated that an appropriate option for the treatment of postpartum anemia is ferric carboxymaltose (FCM), a more recent dextran-free iron formulation that permits single and higher doses (up to 1000 mg) of IV iron infusion. Furthermore, injection of FCM in the dose of 1000 mg given in a single dose before discharge in postpartum women helped in reducing postpartum anemia (PPA) without any significant adverse effects. Hence such substantial reports showing the advantages of FCM promote market growth over the forecast period.

Therefore, factors such as best-in-class safety and efficacy, reduced dosing interval, improved clinical significance, and cost-effectiveness have fuelled the growth of the FCM segment in the intravenous iron drugs market.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period.

The rising prevalence of chronic kidney disease and gastrointestinal illnesses and cancers in North America contributed to its regional dominance in the intravenous iron drugs market over the forecast period. Besides this, the approval and launch of new intravenous medications in the region have further propelled the market growth.

According to the Centers for Disease Control and Prevention (CDC), in 2021, chronic kidney disease (CKD) affects 15 percent of adults in the United States. CKD affects more than one in seven persons in the United States accounting for approximately 37 million people in 2021. Age is also the biggest factor for CKD in the United States. For instance, CKD is more common in adults over 65 years old (38%) than in people 45–64 years old (12%) or 18–44 years old (18–44 years old) (6%). Anemia is a complication that affects most individuals with advanced CKD. The relative deficiency of erythropoietin production is the major driver of anemia. Iron deficiency contributes to impaired erythropoiesis in CKD patients. People who have CKD are prone to use intravenous iron products to improve their health and body iron levels. This propels market growth of intravenous iron drugs over the forecast period.

Furthermore, gastrointestinal illness such as irritable bowel disease (IBD) is also the most common complication in the United States and Canada. According to the Government of Canada, 260,000 Canadians were affected by IBD in 2021. Patients with IBD are commonly found to have iron deficiency anemia (IDA) secondary to chronic blood loss, and impaired iron absorption due to tissue inflammation. Hence the chance of using IV iron drugs in the studied area is boosted due to the high prevalence of such diseases.

Intravenous iron drugs are preferred in the treatment regimen of chronic kidney disease and Irritable Bowel disease. The rising prevalence of these target diseases in North America has accounted for the highest market share in this region for the intravenous iron drugs market.

Competitive Landscape

The intravenous iron drugs market is consolidated and competitive and consists of a few players across the globe. In terms of market share, a few of the major players are currently dominating the market. Some of the companies that hold a significant market share are CSL Limited (Vifor Pharma Management Ltd.), AbbVie (Allergan), Covis Pharma GmbH (AMAG Pharmaceuticals, Inc), Sanofi, Pharmocos, Shield Therapeutics Rockwell Medical, American Regent among others.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.